Vimarsana
Biggest News Aggregation in the World

Page 34 - Beigene News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Beigene. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Beigene Today - Breaking & Trending Today

BeiGene (NASDAQ:BGNE) Upgraded to "Buy" at Zacks Investment Research - Vimarsana News

BeiGene (NASDAQ:BGNE) Upgraded to "Buy" at Zacks Investment Research

BeiGene (NASDAQ:BGNE – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “buy” rating in a research report issued to clients and investors on Monday, Zacks.com reports. The brokerage currently has a $179.00 price objective on the stock. Zacks Investment Research‘s price objective points to a potential upside of 7.49% […]

BeiGene Breaks Ground on New Manufacturing and Clinical R&D Center at the Princeton West Innovation Campus in New Jersey - Vimarsana News

BeiGene Breaks Ground on New Manufacturing and Clinical R&D Center at the Princeton West Innovation Campus in New Jersey

Flagship U.S. Facility Will Include Biologic Manufacturing and Late Stage Research and Clinical Development of Innovative Cancer Medicines Sixth U.S. Location Adds to Global Expansion and Brings

Astellas, BeiGene, Serum Institute—Fierce Pharma Asia - Vimarsana News

Astellas, BeiGene, Serum Institute—Fierce Pharma Asia

Astellas takes gene therapy hit. Novartis and BeiGene post PD-1 win. Serum Institute halts COVID vaccine production.

Global Phase 3 Trial of BeiGene's PD-1 Inhibitor, Tislelizumab, in Combination with Chemotherapy Meets Primary Endpoint in First-Line Advanced Esophageal Squamous Cell Carcinoma Seite 1 - Vimarsana News

Global Phase 3 Trial of BeiGene's PD-1 Inhibitor, Tislelizumab, in Combination with Chemotherapy Meets Primary Endpoint in First-Line Advanced Esophageal Squamous Cell Carcinoma Seite 1

27.04.2022 - BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced the ... Seite 1

BeiGene to Present Clinical Data from Innovative Oncology Portfolio at 2022 ASCO Annual Meeting - Vimarsana News

BeiGene to Present Clinical Data from Innovative Oncology Portfolio at 2022 ASCO Annual Meeting

Plenary presentation of Phase 3 tislelizumab trial in first-line RM-NPC Primary analysis of zanubrutinib Phase 2 ROSEWOOD trial in follicular lymphoma Long-term data from zanubrutinib Phase 3